April 9, 2018 / 9:33 AM / 8 months ago

BRIEF-Oncology Venture Exercises Option To In License Dovitinib A Phase 3 Multi Tyrosine Kinase Inhibitor

April 9 (Reuters) - Oncology Venture Sweden AB:

* ONCOLOGY VENTURE EXERCISES OPTION TO IN LICENSE DOVITINIB A PHASE 3 MULTI TYROSINE KINASE INHIBITOR

* ENTERED INTO AN AGREEMENT WITH NOVARTIS FOR EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE DOVITINIB

* NOVARTIS WILL RECEIVE AN UPFRONT PAYMENT, DEVELOPMENT MILESTONES, AND ROYALTIES ON SALES.

* NOVARTIS WILL BE ISSUED A CONVERTIBLE DEBT-TO-EQUITY NOTE IN A SPINOUT COMPANY THAT OV HAS CREATED

* WILL FURTHER REFINE DOVITINIB DRP® BIOMARKER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below